Avanos Medical (AVNS) 10-Q 5 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	3 Months Ended
	Mar. 31, 2015	1-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	HALYARD HEALTH, INC.
Entity Central Index Key	1606498
Current Fiscal Year End Date	-19
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		46,535,951

CONDENSED_CONSOLIDATED_INCOME_

CONDENSED CONSOLIDATED INCOME STATEMENT (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Net Sales (including related party sales of $0 and $21.3)	$394.20	$410.70
Cost of products sold (including related party purchases of $0 and $19.4)	262.1	255.7
Gross Profit	132.1	155
Research and development expenses	6	8.3
Selling and general expenses	97.2	85.5
Other income, net	-12	-0.5
Operating Profit	40.9	61.7
Interest income	0.1	1
Interest expense	-8.3	0
Income Before Income Taxes	32.7	62.7
Provision for income taxes	-11	-21.3
Net Income	$21.70	$41.40
Per Share Basis (dollars per share)
Basic	$0.47	$0.89
Diluted	$0.46	$0.89

CONDENSED_CONSOLIDATED_INCOME_1

CONDENSED CONSOLIDATED INCOME STATEMENT (Parenthetical) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net Sales	$394.20	$410.70
Cost of products sold	262.1	255.7
Kimberly Clark and Affiliates | Affiliated entity
Net Sales	0	21.3
Cost of products sold	$0	$19.40

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE (LOSS) INCOME Statement (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net Income	$21.70	$41.40
Other Comprehensive (Loss) Income, Net of Tax
Unrealized currency translation adjustments	-6.8	2.6
Cash flow hedges	0.3	2.4
Total Other Comprehensive (Loss) Income, Net of Tax	-6.5	5
Comprehensive Income	$15.20	$46.40

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Current Assets
Cash and cash equivalents	$166.20	$149
Accounts receivable, net	226.5	233.9
Inventories	293	283.1
Current deferred income taxes and other current assets	17.4	18.9
Total Current Assets	703.1	684.9
Property, Plant and Equipment, Net	281.8	277.8
Assets Held for Sale	0	2.6
Goodwill	1,422.10	1,426.10
Other Intangible Assets	101.8	108.3
Other Assets	27.6	27.9
TOTAL ASSETS	2,536.40	2,527.60
Current Liabilities
Debt payable within one year	3.9	3.9
Trade accounts payable	192.1	168.7
Accrued expenses	145	183.4
Total Current Liabilities	341	356
Long-Term Debt	631.4	632.3
Other Long-Term Liabilities	52.2	48.1
Total Liabilities	1,024.60	1,036.40
Commitments and Contingencies
Stockholders’ Equity
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued	0	0
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,535,951 outstanding as of March 31, 2015 and December 31, 2014	0.5	0.5
Additional paid-in capital	1,507.90	1,502.50
Retained earnings	29	7.3
Accumulated other comprehensive loss	-25.6	-19.1
Total Stockholders’ Equity	1,511.80	1,491.20
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$2,536.40	$2,527.60

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	46,535,951	46,535,951
Common stock, shares outstanding	46,535,951	46,535,951

CONDENSED_CONSOLIDATED_CASH_FL

CONDENSED CONSOLIDATED CASH FLOW STATEMENT (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating Activities
Net Income	$21.70	$41.40
Depreciation and amortization	16.4	17.3
Stock-based compensation expense	5.4	0.7
Net (gain) loss on asset dispositions	-12.1	1.5
Changes in operating assets and liabilities:
Accounts receivable	7.5	5.4
Inventories	-9.9	-2.1
Prepaid expenses and other assets	1.3	0.6
Accounts payable	36.5	-7.9
Accrued expenses	-26.5	-34
Other	-0.6	2.7
Cash Provided by Operating Activities	39.7	25.6
Investing Activities
Capital expenditures	-27.7	-7.5
Proceeds from property dispositions	7.7	0
Cash Used in Investing Activities	-20	-7.5
Financing Activities
Debt proceeds	0	0.3
Debt repayments	-1	-2.9
Change in Kimberly-Clark's net investment	0	-24.4
Other	0	0.9
Cash Used in Financing Activities	-1	-26.1
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-1.5	-0.3
Increase (Decrease) in Cash and Cash Equivalents	17.2	-8.3
Cash and Cash Equivalents - Beginning of Period	149	44.1
Cash and Cash Equivalents - End of Period	$166.20	$35.80

Accounting_Policies

Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Accounting Policies	Accounting Policies
	Background and Basis of Presentation
	Halyard Health, Inc. is a global business which seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. Our products and solutions are designed to address some of today’s most important healthcare needs, namely, preventing infections and reducing the use of narcotics while helping patients move from surgery to recovery. We market and support the efficacy, safety and economic benefit of our products with a significant body of clinical evidence. We operate in two business segments: Surgical and Infection Prevention (“S&IP”) and Medical Devices.
	References to “Halyard,” “we,” “our” and “us” refer to Halyard Health, Inc. References to “Kimberly-Clark” mean Kimberly-Clark Corporation, a Delaware corporation, and its subsidiaries, other than Halyard, unless the context otherwise requires.
	In November 2013, Kimberly-Clark announced its intention to evaluate a potential tax-free spin-off of its health care business (the “Spin-off”). Halyard Health, Inc. was incorporated in Delaware in February 2014 for the purpose of holding the health care business following the separation. The Spin-off was completed on October 31, 2014 and Kimberly-Clark’s health care business became Halyard Health, Inc.
	The condensed consolidated financial statements for the three months ended March 31, 2015 represent our financial position, results of operations and cash flows as an independent publicly-traded company. The condensed combined financial statements for the three months ended March 31, 2014 represent the results of operations and cash flows of Kimberly-Clark’s health care business.
	Interim Financial Statements
	We prepared the accompanying condensed consolidated financial statements according to accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Accordingly, the condensed consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2014. Our unaudited interim condensed consolidated financial statements contain all material adjustments which are of a normal and recurring nature necessary to fairly state our financial condition, results of operations and cash flows for the periods presented. Certain prior period amounts have been conformed to current presentation.
	Use of Estimates
	Preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting periods. Estimates are used in accounting for, among other things, distributor rebate accruals, future cash flows associated with impairment testing for goodwill and long-lived assets, loss contingencies, and deferred tax assets and potential income tax assessments. Actual results could differ from these estimates, and the effect of the change could be material to our financial statements. Changes in these estimates are recorded when known.
	As described in our Annual Report on Form 10-K, we completed the required annual testing of goodwill for impairment for all reporting units using the beginning of the third quarter of 2014 as the measurement date and our analysis indicated that we had no impairment of goodwill. During the three months ended March 31, 2015, we determined that there were no conditions or changes that would indicate that our goodwill may be impaired.
	New Accounting Standards
	In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. This ASU addresses the different balance sheet presentation requirements for debt issuance costs, discounts and premiums under the FASB Accounting Standards Codification (“ASC”) Subtopic 835-30, Interest - Imputation of Interest. Currently, GAAP recognizes debt issuance costs as a deferred charge (i.e., an asset), which conflicts with FASB Concepts Statement No. 6, Elements of Financial Statements, which says that debt issuance costs are similar to debt discounts and reduce the proceeds of borrowing, thereby increasing the effective interest rate. Accordingly, ASU No. 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU will become effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption will be permitted for financial statements that have not been previously issued. Application of this ASU will result in the reclassification of our debt issuance costs of approximately $10 million as of each quarter ended March 31, 2016 and December 31, 2015 from other assets to long-term debt.
	In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. ASU No. 2015-01 eliminates ASC Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, which, until now, required that an entity separately classify, present, and disclose transactions and events that were determined to be both unusual and infrequent as extraordinary items. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments (i) prospectively or (ii) retrospectively to all prior periods presented in the financial statements. The application of this ASU is not expected to have a material effect on our financial position, results of operations and cash flows.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern, that will require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. The new standard defines substantial doubt and provides example indicators. Disclosures will be required if conditions give rise to substantial doubt. However, management will need to assess if its plans will alleviate substantial doubt to determine the specific disclosures. This ASU will become effective for annual periods ending after December 15, 2016. Earlier application is permitted. The application of this ASU is not expected to have a material effect on our financial position, results of operations and cash flows.
	In May 2014, the FASB issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. This ASU is effective for public entities for annual and interim periods beginning after December 15, 2017. Adoption prior to interim periods beginning after December 15, 2016 is not permitted. The guidance permits two implementation approaches, one requiring retrospective application of the new ASU with restatement of prior years and one requiring prospective application of the new ASU with disclosure of results under old standards. The effects of this ASU on our financial position, results of operations and cash flows are not yet known.

SpinOff_Transition_Costs

Spin-Off Transition Costs	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Spin-Off Transition Costs	Spin-Off Transition Costs
	Completion of the Sale of Disposable Glove Facility
	In June 2014, Kimberly-Clark initiated a plan to exit one of the disposable glove facilities in Thailand and outsource the related production to improve the competitive position of the S&IP business. In December 2014, we entered into a definitive agreement to sell the disposable glove facility to a third party. We received advance cash payments of $8 million before the end of 2014, which was included in “Accrued Expenses” in the accompanying condensed consolidated balance sheet as of December 31, 2014. The net book value of the disposable glove facility was $3 million and was classified as “Assets Held for Sale” in the accompanying condensed consolidated balance sheet as of December 31, 2014. We received the remaining $8 million of the sale price when the sale closed in January 2015. The sale resulted in a net gain of $12 million, which was recorded in “Other income, net” in the accompanying condensed consolidated income statement. There were no remaining accrued expenses related to this plan as of March 31, 2015.
	Manufacturing Alignment, Marketing and Rebranding and Incremental Transition Services from Kimberly-Clark
	As a result of the Spin-off, we are making changes to our plant and equipment, primarily in North America to align with our manufacturing requirements. These changes will include modifications to certain equipment and the movement of health-care equipment from Kimberly-Clark locations to Halyard facilities.
	We are undertaking efforts to ensure our customers transition from the Kimberly-Clark brand to our Halyard-branded products. We have entered into a royalty agreement under which we have access to use the Kimberly-Clark brand for up to 24 months as we manage the packaging changes with global regulatory bodies. Royalties are required to be paid for products sold bearing the Kimberly-Clark brand only. In addition to royalty expense, we expect to incur costs for packaging, marketing and regulatory approval in order to complete this transition.
	While building our own capabilities as a stand-alone company, we have entered into transition service agreements with Kimberly-Clark to provide temporary supporting services until we have the necessary resources and infrastructure in place.
	In the three months ended March 31, 2015 we have incurred $11 million, ($7 million, net of tax) for the above programs.

Supplemental_Balance_Sheet_Inf

Supplemental Balance Sheet Information	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Balance Sheet Information	Supplemental Balance Sheet Information
	Accounts Receivable
	Accounts receivable consist of the following (in millions):
		March 31, 2015			December 31, 2014
	Accounts receivable	$	227.7		$	234.9
	Allowance for sales discounts and doubtful accounts	(1.2		)	(1.0		)
	Accounts receivable, net	$	226.5		$	233.9
	Inventories
	Inventories at the lower of cost (determined on the LIFO/FIFO or weighted-average cost methods) or market consist of the following (in millions):
		March 31, 2015									December 31, 2014
		LIFO			Non-			Total			LIFO			Non-			Total
					LIFO									LIFO
	Raw materials	$	51.3		$	0.7		$	52		$	48.4		$	1.3		$	49.7
	Work in process	54.9			0.5			55.4			47.7			0.3			48
	Finished goods	157.6			36.9			194.5			157.8			37.5			195.3
	Supplies and other	—			12			12			—			11.8			11.8
		263.8			50.1			313.9			253.9			50.9			304.8
	Excess of FIFO or weighted-average cost over LIFO cost	(20.9		)	—			(20.9		)	(21.7		)	—			(21.7		)
	Total	$	242.9		$	50.1		$	293		$	232.2		$	50.9		$	283.1
	Property, Plant and Equipment
	Property, plant and equipment consists of the following (in millions):
		March 31, 2015			December 31, 2014
	Land	$	2.3		$	2.3
	Buildings	83.8			67.9
	Machinery and equipment	451.8			436.3
	Construction in progress	43.3			62.2
		581.2			568.7
	Less accumulated depreciation	(299.4		)	(290.9		)
	Total	$	281.8		$	277.8
	Depreciation expense was $10 million and $9 million for the three months ended March 31, 2015 and 2014, respectively.
	Goodwill and Intangible Assets
	The changes in the carrying amount of goodwill by business segment are as follows (in millions):
		S&IP			Medical Devices			Total
	Balance at December 31, 2014	$	744.5		$	681.6		$	1,426.10
	Currency translation adjustment	(2.2		)	(1.8		)	(4.0		)
	Balance at March 31, 2015	$	742.3		$	679.8		$	1,422.10
	As of March 31, 2015 and December 31, 2014, we had intangible assets with indefinite useful lives of $7 million related to acquired in-process research and development.
	Intangible assets subject to amortization consist of the following (in millions):
		March 31, 2015									December 31, 2014
		Gross			Accumulated			Net Carrying Amount			Gross			Accumulated			Net Carrying Amount
		Carrying			Amortization						Carrying			Amortization
		Amount									Amount
	Trademarks	$	126.6		$	(87.2	)	$	39.4		$	126.6		$	(86.1	)	$	40.5
	Patents and acquired technologies	149.1			(103.8		)	45.3			149.1			(99.3		)	49.8
	Other	48.3			(37.9		)	10.4			48.3			(37.0		)	11.3
	Total	$	324		$	(228.9	)	$	95.1		$	324		$	(222.4	)	$	101.6
	Amortization expense for intangible assets was $6 million and $8 million for the three months ended March 31, 2015 and 2014, respectively. We estimate amortization expense for the remainder of 2015 and the following four years and beyond will be as follows (in millions):
	For the years ending December 31,
	2015		$	18.9
	2016		20.2
	2017		14.9
	2018		11.1
	2019		6.9
	Thereafter		23.1
	Total		$	95.1
	Accrued Expenses
	Accrued expenses consist of the following (in millions):
		March 31, 2015			December 31, 2014
	Accrued rebates	$	68.3		$	82.2
	Accrued salaries and wages	27.4			46.4
	Accrued taxes - income and other	23.8			23.4
	Deposit received on pending sale of assets	—			7.8
	Other	25.5			23.6
	Total	$	145		$	183.4
Other Long-Term Liabilities
Other long-term liabilities consist of the following (in millions):
	March 31, 2015			December 31, 2014
Deferred income taxes	$	27.8		$	27.9
Taxes payable	1.6			1.6
Other	22.8			18.6
Total	$	52.2		$	48.1

LongTerm_Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt
	As of March 31, 2015 and December 31, 2014, our debt balances were as follows (in millions):
		Weighted-Average Interest Rate		Maturities	March 31, 2015		December 31, 2014
	Senior Secured Term Loan	4	%	2021	$	385.3	$	386.2
	Senior Unsecured Notes	6.25	%	2022	250		250
	Total long-term debt				635.3		636.2
	Less debt payable within one year				3.9		3.9
	Long-term portion				$	631.4	$	632.3
	Senior Unsecured Notes
	The senior unsecured notes (the “Notes”) will mature on October 15, 2022 and interest will accrue at a rate of 6.25% per annum and will be payable semi-annually in arrears on April 15 and October 15 of each year.
	Senior Secured Term Loan and Revolving Credit Facility
	The senior secured term loan is under a credit agreement that established credit facilities in an aggregate principal amount of $640 million, including a five-year senior secured revolving credit facility allowing borrowings of up to $250 million, with a letter of credit sub-facility in an amount of $75 million and a swingline sub-facility in an amount of $25 million (the “Revolving Credit Facility”), and a seven-year senior secured term loan of $390 million (the “Term Loan Facility”). The Term Loan Facility is secured by substantially all of our assets located in the United States and a certain percentage of our foreign subsidiaries’ capital stock.
	On April 30, 2015, we made a $50 million principal payment on our senior secured term loan without prepayment penalties pursuant to the terms of the governing loan agreement. We recognized a charge of $1 million in the second quarter of 2015 related to the write-off of related debt issuance costs and original issue discount.
	Borrowings under the Term Loan Facility will bear interest, at Halyard’s option, at either (i) a reserve-adjusted LIBOR rate, subject to a floor of 0.75%, plus 3.25%, or (ii) a base rate, subject to a floor of 0.75%, (calculated as the greatest of (1) the prime rate, (2) the U.S. federal funds effective rate plus 0.50% or (3) the one month LIBOR rate plus 1.00%) plus 2.25%. The Term Loan Facility requires quarterly amortization payments equal to 0.25% of the aggregate principal amount of the term loans outstanding on the closing date. As of March 31, 2015, the interest rate in effect for the Term Loan Facility was 4.00%.
	Borrowings under the Revolving Credit Facility will bear interest, at Halyard’s option, at either (i) a reserve-adjusted LIBOR rate, plus a margin initially equal to 2.25% and then, following Halyard’s delivery under the credit agreement of Halyard’s financial statements for Halyard’s fiscal quarter ending March 31, 2015, ranging between 1.75% to 2.50% per annum, depending on Halyard’s consolidated total leverage ratio, or (ii) the base rate plus a margin initially equal to 1.25% and then, following Halyard’s delivery of those financial statements, ranging between 0.75% to 1.50% per annum, depending on Halyard’s consolidated total leverage ratio. The unused portion of Halyard’s Revolving Credit Facility will be subject to a commitment fee equal to (i) 0.25% per annum, when Halyard’s consolidated total leverage ratio is less than 2.25 to 1.00 and (ii) 0.40% per annum, otherwise. As of March 31, 2015, we had no borrowings and letters of credit of $3 million outstanding under the Revolving Credit Facility, leaving $247 million available for borrowing.

Derivative_Financial_Instrumen

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial Instruments
	The derivative liabilities for foreign exchange contracts as of March 31, 2015 and December 31, 2014 were $1 million and $1 million, respectively, and are included in the condensed consolidated balance sheet in accrued expenses. The derivative assets for foreign exchange contracts as of March 31, 2015 and December 31, 2014 were not significant.
	For derivative instruments that are designated and qualify as cash flow hedges, gains or losses recognized to earnings were not significant in the three months ended March 31, 2015 and 2014. As of March 31, 2015, the aggregate notional values of outstanding foreign exchange derivative contracts designated as cash flow hedges were $39 million. Cash flow hedges resulted in no significant ineffectiveness in the three months ended March 31, 2015 and 2014. For the three months ended March 31, 2015 and 2014, no gains or losses were reclassified into earnings as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At March 31, 2015, amounts to be reclassified from AOCI during the next twelve months are not expected to be significant. The maximum maturity of cash flow hedges in place at March 31, 2015 is March 2016.
	Gains or losses on undesignated foreign exchange hedging instruments are immediately recognized in other income and expense, net. These gains or losses have not been significant for the three months ended March 31, 2015 and 2014. The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. As of March 31, 2015, the notional amount of these undesignated derivative instruments was $70 million.

Fair_Value_Information

Fair Value Information	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Information	Fair Value Information
	The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:
	Level 1—Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.
	Level 2—Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.
	Level 3—Prices or valuations that require inputs that are significant to the valuation and are unobservable.
	A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	In the three months ended March 31, 2015, there were no transfers among Level 1, 2 or 3 fair value determinations.
	The derivative liabilities for foreign exchange contracts were $1 million as of both March 31, 2015 and December 31, 2014 and are included in the condensed consolidated balance sheet in accrued expenses. These derivatives are classified as Level 2 of the fair value hierarchy. The fair values of derivatives used to manage foreign currency risk is based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates.
	The following table includes the fair value of our financial instruments for which disclosure of fair value is required (in millions):
			March 31, 2015				December 31, 2014
		Fair Value	Carrying		Estimated		Carrying		Estimated
		Hierarchy	Amount		Fair		Amount		Fair
		Level			Value				Value
	Assets
	Cash and cash equivalents	1	$	166.2	$	166.2	$	149	$	149
	Liabilities
	Debt	2	635.3		656.2		636.2		644
	Cash equivalents are recorded at cost, which approximates fair value due to their short-term nature.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income
	The changes in the components of Accumulated Other Comprehensive Income (“AOCI”) are as follows (in millions):
		Three Months Ended March 31,
		2015			2014
	Unrealized translation	$	(6.8	)	$	2.6
	Cash flow hedges	0.5			2.9
		(6.3		)	5.5
	Tax effect	(0.2		)	(0.5		)
	Change in AOCI	$	(6.5	)	$	5

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation
	Aggregate stock-based compensation expense for the three months ended March 31, 2015 was $5 million, which reflects expense incurred for stock option and restricted stock unit awards granted under the Halyard Health, Inc. Equity Participation Plan and the Halyard Health, Inc. Outside Directors’ Compensation Plan (together, the “Plans”). Aggregate stock-based compensation expense for the three months ended March 31, 2014 was $1 million and reflects expense allocated to us for awards granted under Kimberly-Clark’s equity incentive plans.
	Stock Options
	Stock-based compensation expense related to stock options was $1 million for the three months ended March 31, 2015. A summary of stock option activity under the Plans is presented below:
		Shares		Weighted-			Weighted-	Aggregate
		(in thousands)		Average			Average	Intrinsic
				Exercise			Remaining	Value
				Price			Contractual	(in millions)
							Term (Years)
	Outstanding at December 31, 2014	611		$	34.94
	Granted	336		45.51
	Forfeitures	(21	)	35.52
	Outstanding at March 31, 2015	926		$	38.76		9.1	$	9.7
	The following table summarizes information about options outstanding as of March 31, 2015:
				Stock Options Outstanding
	Range of			Shares		Weighted-
	Exercise Prices			(in thousands)		Average
						Remaining
						Contractual
						Term (Years)
	$25	to	$35	252		7.8
	$35	to	$45	339		9.3
	$45+			335		9.9
				926		9.1
	There were no vested and exercisable options outstanding at March 31, 2015.
	Restricted Share Units
	Stock-based compensation expense related to restricted share units was $4 million for the three months ended March 31, 2015. A summary of restricted share unit activity is presented below:
		Shares		Weighted-
		(in thousands)		Average
				Fair Value
	Outstanding at December 31, 2014	375		$	37.88
	Granted	103		45.63
	Forfeitures	(8	)	37.88
	Outstanding at March 31, 2015	470		$	39.59
	Vested at March 31, 2015	27		$	44.32
	Prior Year Expense under Kimberly-Clark Equity Incentive Plans
	Kimberly-Clark maintains several equity incentive plans in which our executives and employees participated prior to the Spin-off. All awards granted under Kimberly-Clark’s plans were based on common shares of Kimberly-Clark stock and, as such, were reflected in Kimberly-Clark’s consolidated statements of equity and not in our combined statement of invested equity. Prior to the Spin-off, Kimberly-Clark allocated stock-based compensation expense to Halyard for employees of Kimberly-Clark’s health care business that became Halyard employees upon the Spin-off. Stock-based compensation expense charged to us by Kimberly-Clark under their incentive plans was $1 million for the three months ended March 31, 2014.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	We are subject to various legal proceedings, claims and governmental inspections, audits or investigations pertaining to issues such as contract disputes, product liability, tax matters, patents and trademarks, advertising, governmental regulations, employment and other matters, including the matters described below. Under the terms of the distribution agreement we entered into with Kimberly-Clark prior to the Spin-off, legal proceedings, claims and other liabilities that are primarily related to our business will be our responsibility and we will be obligated to indemnify and hold Kimberly-Clark harmless for such matters. The only exception to this general obligation relates to the pain pump litigation referenced in the next paragraph below. Although the results of litigation and claims cannot be predicted with certainty, we believe that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, individually or in the aggregate, on our business, financial condition, results of operations or liquidity.
	We are one of several manufacturers of continuous infusion medical devices, such as our ON-Q PAINBUSTER pain pumps, that are involved in several different pending or threatened litigation matters from multiple plaintiffs alleging that use of the continuous infusion device to deliver anesthetics directly into a synovial joint after surgery resulted in postarthroscopic glenohumeral chondrolysis, or a disintegration of the cartilage covering the bones in the joint (typically, in the shoulder). Plaintiffs generally seek monetary damages and attorneys’ fees. While Kimberly-Clark is retaining the liabilities related to these matters, the distribution agreement between us and Kimberly-Clark provides that we will indemnify Kimberly-Clark for any such claims or causes of actions arising after the Spin-off.
	We operate in an industry characterized by extensive patent litigation and competitors may claim that our products infringe upon their intellectual property. Resolution of patent litigation or other intellectual property claims is typically time consuming and costly and can result in significant damage awards and injunctions that could prevent the manufacture and sale of the affected products or require us to make significant royalty payments in order to continue selling the affected products. At any given time we are involved as either a plaintiff or a defendant in a number of patent infringement actions, the outcomes of which may not be known for prolonged periods of time.
	We are subject to federal, state and local environmental protection laws and regulations with respect to our business operations and are operating in compliance with, or taking action aimed at ensuring compliance with, these laws and regulations. None of our compliance obligations with environmental protection laws and regulations, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition, results of operations or liquidity.

Earnings_Per_Share_EPS

Earnings Per Share ("EPS")	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share (“EPS”)	Earnings Per Share (“EPS”)
	Basic EPS is calculated by dividing net income by the weighted average number of common shares outstanding during each period. Diluted earnings per share is calculated by dividing net income by the weighted average number of common shares outstanding and the effect of all dilutive common stock equivalents outstanding during each period, as determined using the treasury stock method. The contribution of Kimberly-Clark’s Health Care business to us was treated as a reorganization of entities under common control under Kimberly-Clark. Consequently, we are retrospectively reporting EPS for the prior year using the 46.5 million weighted average shares outstanding as of the Spin-off date for both basic and diluted EPS as no Halyard common stock or dilutive stock-based compensation awards were authorized or outstanding prior to the Spin-off.
	The calculation of basic and diluted earnings per share for the three months ended March 31, 2015 and March 31, 2014 is set forth in the following table (in millions, except per share amounts):
		Three Months Ended March 31,
		2015		2014
	Net income	$	21.7	$	41.4
	Weighted Average Shares Outstanding:
	Basic weighted average shares outstanding	46.5		46.5
	Dilutive effect of stock options and restricted share unit awards	0.2		—
	Diluted weighted average shares outstanding	46.7		46.5
	Earnings Per Share
	Basic	$	0.47	$	0.89
	Diluted	$	0.46	$	0.89

Business_Segment_Information

Business Segment Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information
	Information concerning unaudited consolidated operations by business segment is presented in the following table (in millions):
		Three Months Ended March 31,
		2015			2014
	Net Sales
	S&IP	$	254.8		$	275.5
	Medical Devices	122.3			129.6
	Corporate & Other(a)	17.1			5.6
	Total Net Sales	394.2			410.7
	Operating Profit
	S&IP	19.5			40.1
	Medical Devices	24.8			31.4
	Corporate & Other(b)	(15.4		)	(10.3		)
	Other income, net(c)	12			0.5
	Total Operating Profit	40.9			61.7
	Interest income	0.1			1
	Interest expense	(8.3		)	—
	Income before Income Taxes	$	32.7		$	62.7
	_________________________________________________
	(a)	Corporate and Other net sales include sales of non-healthcare products to Kimberly-Clark.
	(b)	Corporate and Other for the three months ended March 31, 2015 includes $11 million of post-spin related transition expenses. Corporate and Other for the three months ended March 31, 2014 includes $7 million of spin-off related transaction costs.
	(c)	Other income, net includes a $12 million net gain on the disposal of one of our disposable glove facilities in Thailand.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions
	In the prior year, we utilized manufacturing facilities and resources managed by affiliates of Kimberly-Clark to conduct our business. The expenses associated with these transactions, which primarily relate to production of semi-finished goods for our S&IP business, are included in cost of products sold in our combined income statement for the three months ended March 31, 2014. Following the Spin-off, Kimberly-Clark is not considered a related party.
	In the prior year, our combined financial statements include certain expenses of Kimberly-Clark which were allocated to us for certain functions, including general expenses related to supply chain, finance, legal, information technology, human resources, compliance, shared services, insurance, employee benefits and incentives and stock-based compensation. These expenses were allocated to us on the basis of direct usage when identifiable, with the remainder allocated on the relative percentage of net sales or headcount. The total amount of these allocations from Kimberly-Clark was approximately as follows (in millions):
		Three Months Ended March 31, 2014
	Cost of products sold	$	6
	Selling and general expenses	16
	Research expenses	3
	Total	$	25

Accounting_Policies_Policies

Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Background and Basis of Presentation	Background and Basis of Presentation
	Halyard Health, Inc. is a global business which seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. Our products and solutions are designed to address some of today’s most important healthcare needs, namely, preventing infections and reducing the use of narcotics while helping patients move from surgery to recovery. We market and support the efficacy, safety and economic benefit of our products with a significant body of clinical evidence. We operate in two business segments: Surgical and Infection Prevention (“S&IP”) and Medical Devices.
	References to “Halyard,” “we,” “our” and “us” refer to Halyard Health, Inc. References to “Kimberly-Clark” mean Kimberly-Clark Corporation, a Delaware corporation, and its subsidiaries, other than Halyard, unless the context otherwise requires.
	In November 2013, Kimberly-Clark announced its intention to evaluate a potential tax-free spin-off of its health care business (the “Spin-off”). Halyard Health, Inc. was incorporated in Delaware in February 2014 for the purpose of holding the health care business following the separation. The Spin-off was completed on October 31, 2014 and Kimberly-Clark’s health care business became Halyard Health, Inc.
	The condensed consolidated financial statements for the three months ended March 31, 2015 represent our financial position, results of operations and cash flows as an independent publicly-traded company. The condensed combined financial statements for the three months ended March 31, 2014 represent the results of operations and cash flows of Kimberly-Clark’s health care business.
	Interim Financial Statements
	We prepared the accompanying condensed consolidated financial statements according to accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Accordingly, the condensed consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2014. Our unaudited interim condensed consolidated financial statements contain all material adjustments which are of a normal and recurring nature necessary to fairly state our financial condition, results of operations and cash flows for the periods presented. Certain prior period amounts have been conformed to current presentation.
Use of Estimates	Use of Estimates
	Preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting periods. Estimates are used in accounting for, among other things, distributor rebate accruals, future cash flows associated with impairment testing for goodwill and long-lived assets, loss contingencies, and deferred tax assets and potential income tax assessments. Actual results could differ from these estimates, and the effect of the change could be material to our financial statements. Changes in these estimates are recorded when known.
	As described in our Annual Report on Form 10-K, we completed the required annual testing of goodwill for impairment for all reporting units using the beginning of the third quarter of 2014 as the measurement date and our analysis indicated that we had no impairment of goodwill. During the three months ended March 31, 2015, we determined that there were no conditions or changes that would indicate that our goodwill may be impaired.
New Accounting Standards	New Accounting Standards
	In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. This ASU addresses the different balance sheet presentation requirements for debt issuance costs, discounts and premiums under the FASB Accounting Standards Codification (“ASC”) Subtopic 835-30, Interest - Imputation of Interest. Currently, GAAP recognizes debt issuance costs as a deferred charge (i.e., an asset), which conflicts with FASB Concepts Statement No. 6, Elements of Financial Statements, which says that debt issuance costs are similar to debt discounts and reduce the proceeds of borrowing, thereby increasing the effective interest rate. Accordingly, ASU No. 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU will become effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption will be permitted for financial statements that have not been previously issued. Application of this ASU will result in the reclassification of our debt issuance costs of approximately $10 million as of each quarter ended March 31, 2016 and December 31, 2015 from other assets to long-term debt.
	In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. ASU No. 2015-01 eliminates ASC Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, which, until now, required that an entity separately classify, present, and disclose transactions and events that were determined to be both unusual and infrequent as extraordinary items. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments (i) prospectively or (ii) retrospectively to all prior periods presented in the financial statements. The application of this ASU is not expected to have a material effect on our financial position, results of operations and cash flows.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern, that will require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. The new standard defines substantial doubt and provides example indicators. Disclosures will be required if conditions give rise to substantial doubt. However, management will need to assess if its plans will alleviate substantial doubt to determine the specific disclosures. This ASU will become effective for annual periods ending after December 15, 2016. Earlier application is permitted. The application of this ASU is not expected to have a material effect on our financial position, results of operations and cash flows.
	In May 2014, the FASB issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. This ASU is effective for public entities for annual and interim periods beginning after December 15, 2017. Adoption prior to interim periods beginning after December 15, 2016 is not permitted. The guidance permits two implementation approaches, one requiring retrospective application of the new ASU with restatement of prior years and one requiring prospective application of the new ASU with disclosure of results under old standards. The effects of this ASU on our financial position, results of operations and cash flows are not yet known.

Supplemental_Balance_Sheet_Inf1

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accounts receivable	Accounts receivable consist of the following (in millions):
		March 31, 2015			December 31, 2014
	Accounts receivable	$	227.7		$	234.9
	Allowance for sales discounts and doubtful accounts	(1.2		)	(1.0		)
	Accounts receivable, net	$	226.5		$	233.9
Schedule of inventories	Inventories at the lower of cost (determined on the LIFO/FIFO or weighted-average cost methods) or market consist of the following (in millions):
		March 31, 2015									December 31, 2014
		LIFO			Non-			Total			LIFO			Non-			Total
					LIFO									LIFO
	Raw materials	$	51.3		$	0.7		$	52		$	48.4		$	1.3		$	49.7
	Work in process	54.9			0.5			55.4			47.7			0.3			48
	Finished goods	157.6			36.9			194.5			157.8			37.5			195.3
	Supplies and other	—			12			12			—			11.8			11.8
		263.8			50.1			313.9			253.9			50.9			304.8
	Excess of FIFO or weighted-average cost over LIFO cost	(20.9		)	—			(20.9		)	(21.7		)	—			(21.7		)
	Total	$	242.9		$	50.1		$	293		$	232.2		$	50.9		$	283.1
Schedule of property, plant and equipment	Property, plant and equipment consists of the following (in millions):
		March 31, 2015			December 31, 2014
	Land	$	2.3		$	2.3
	Buildings	83.8			67.9
	Machinery and equipment	451.8			436.3
	Construction in progress	43.3			62.2
		581.2			568.7
	Less accumulated depreciation	(299.4		)	(290.9		)
	Total	$	281.8		$	277.8
Changes in the carrying amount of goodwill by business segment	The changes in the carrying amount of goodwill by business segment are as follows (in millions):
		S&IP			Medical Devices			Total
	Balance at December 31, 2014	$	744.5		$	681.6		$	1,426.10
	Currency translation adjustment	(2.2		)	(1.8		)	(4.0		)
	Balance at March 31, 2015	$	742.3		$	679.8		$	1,422.10
Schedule of intangible assets subject to amortization	Intangible assets subject to amortization consist of the following (in millions):
		March 31, 2015									December 31, 2014
		Gross			Accumulated			Net Carrying Amount			Gross			Accumulated			Net Carrying Amount
		Carrying			Amortization						Carrying			Amortization
		Amount									Amount
	Trademarks	$	126.6		$	(87.2	)	$	39.4		$	126.6		$	(86.1	)	$	40.5
	Patents and acquired technologies	149.1			(103.8		)	45.3			149.1			(99.3		)	49.8
	Other	48.3			(37.9		)	10.4			48.3			(37.0		)	11.3
	Total	$	324		$	(228.9	)	$	95.1		$	324		$	(222.4	)	$	101.6
Schedule of estimated amortization expense	We estimate amortization expense for the remainder of 2015 and the following four years and beyond will be as follows (in millions):
	For the years ending December 31,
	2015		$	18.9
	2016		20.2
	2017		14.9
	2018		11.1
	2019		6.9
	Thereafter		23.1
	Total		$	95.1
Schedule of accrued expenses	Accrued expenses consist of the following (in millions):
		March 31, 2015			December 31, 2014
	Accrued rebates	$	68.3		$	82.2
	Accrued salaries and wages	27.4			46.4
	Accrued taxes - income and other	23.8			23.4
	Deposit received on pending sale of assets	—			7.8
	Other	25.5			23.6
	Total	$	145		$	183.4
Schedule of other long-term liabilities	Other long-term liabilities consist of the following (in millions):
		March 31, 2015			December 31, 2014
	Deferred income taxes	$	27.8		$	27.9
	Taxes payable	1.6			1.6
	Other	22.8			18.6
	Total	$	52.2		$	48.1

LongTerm_Debt_Tables

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of debt balances	As of March 31, 2015 and December 31, 2014, our debt balances were as follows (in millions):
		Weighted-Average Interest Rate		Maturities	March 31, 2015		December 31, 2014
	Senior Secured Term Loan	4	%	2021	$	385.3	$	386.2
	Senior Unsecured Notes	6.25	%	2022	250		250
	Total long-term debt				635.3		636.2
	Less debt payable within one year				3.9		3.9
	Long-term portion				$	631.4	$	632.3

Fair_Value_Information_Tables

Fair Value Information (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of fair value of financial instruments	The following table includes the fair value of our financial instruments for which disclosure of fair value is required (in millions):
			March 31, 2015				December 31, 2014
		Fair Value	Carrying		Estimated		Carrying		Estimated
		Hierarchy	Amount		Fair		Amount		Fair
		Level			Value				Value
	Assets
	Cash and cash equivalents	1	$	166.2	$	166.2	$	149	$	149
	Liabilities
	Debt	2	635.3		656.2		636.2		644

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Schedule of changes in the components of Accumulated Other Comprehensive Income, Net of Tax	The changes in the components of Accumulated Other Comprehensive Income (“AOCI”) are as follows (in millions):
		Three Months Ended March 31,
		2015			2014
	Unrealized translation	$	(6.8	)	$	2.6
	Cash flow hedges	0.5			2.9
		(6.3		)	5.5
	Tax effect	(0.2		)	(0.5		)
	Change in AOCI	$	(6.5	)	$	5

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock option activity	A summary of stock option activity under the Plans is presented below:
		Shares		Weighted-			Weighted-	Aggregate
		(in thousands)		Average			Average	Intrinsic
				Exercise			Remaining	Value
				Price			Contractual	(in millions)
							Term (Years)
	Outstanding at December 31, 2014	611		$	34.94
	Granted	336		45.51
	Forfeitures	(21	)	35.52
	Outstanding at March 31, 2015	926		$	38.76		9.1	$	9.7
Schedule of options outstanding by exercise prices	The following table summarizes information about options outstanding as of March 31, 2015:
				Stock Options Outstanding
	Range of			Shares		Weighted-
	Exercise Prices			(in thousands)		Average
						Remaining
						Contractual
						Term (Years)
	$25	to	$35	252		7.8
	$35	to	$45	339		9.3
	$45+			335		9.9
				926		9.1
Summary of restricted share unit activity	A summary of restricted share unit activity is presented below:
		Shares		Weighted-
		(in thousands)		Average
				Fair Value
	Outstanding at December 31, 2014	375		$	37.88
	Granted	103		45.63
	Forfeitures	(8	)	37.88
	Outstanding at March 31, 2015	470		$	39.59
	Vested at March 31, 2015	27		$	44.32

Earnings_Per_Share_EPS_Tables

Earnings Per Share ("EPS") (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Calculation of basic and diluted earnings per share	The calculation of basic and diluted earnings per share for the three months ended March 31, 2015 and March 31, 2014 is set forth in the following table (in millions, except per share amounts):
		Three Months Ended March 31,
		2015		2014
	Net income	$	21.7	$	41.4
	Weighted Average Shares Outstanding:
	Basic weighted average shares outstanding	46.5		46.5
	Dilutive effect of stock options and restricted share unit awards	0.2		—
	Diluted weighted average shares outstanding	46.7		46.5
	Earnings Per Share
	Basic	$	0.47	$	0.89
	Diluted	$	0.46	$	0.89

Business_Segment_Information_T

Business Segment Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Information concerning unaudited consolidated operations by business segment	Information concerning unaudited consolidated operations by business segment is presented in the following table (in millions):
		Three Months Ended March 31,
		2015			2014
	Net Sales
	S&IP	$	254.8		$	275.5
	Medical Devices	122.3			129.6
	Corporate & Other(a)	17.1			5.6
	Total Net Sales	394.2			410.7
	Operating Profit
	S&IP	19.5			40.1
	Medical Devices	24.8			31.4
	Corporate & Other(b)	(15.4		)	(10.3		)
	Other income, net(c)	12			0.5
	Total Operating Profit	40.9			61.7
	Interest income	0.1			1
	Interest expense	(8.3		)	—
	Income before Income Taxes	$	32.7		$	62.7
	_________________________________________________
	(a)	Corporate and Other net sales include sales of non-healthcare products to Kimberly-Clark.
	(b)	Corporate and Other for the three months ended March 31, 2015 includes $11 million of post-spin related transition expenses. Corporate and Other for the three months ended March 31, 2014 includes $7 million of spin-off related transaction costs.
	(c)	Other income, net includes a $12 million net gain on the disposal of one of our disposable glove facilities in Thailand.

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Schedule of expenses allocated from Kimberly-Clark	The total amount of these allocations from Kimberly-Clark was approximately as follows (in millions):
		Three Months Ended March 31, 2014
	Cost of products sold	$	6
	Selling and general expenses	16
	Research expenses	3
	Total	$	25

Accounting_Policies_Details

Accounting Policies (Details) (ASU No. 2015-03, Forecasted, USD $)	Mar. 31, 2016	Dec. 31, 2015
In Millions, unless otherwise specified
ASU No. 2015-03 | Forecasted
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of debt issuance costs	$10	$10

SpinOff_Transition_Costs_Detai

Spin-Off Transition Costs (Details) (USD $)	1 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Deposit received on pending sale of assets		$0		$7.80
Net book value of disposable glove facility		0		2.6
Proceeds from sale of disposable glove facility	8
Duration of royalty agreement, in months		24 months
Spin-off
Restructuring Cost and Reserve [Line Items]
Restructuring charges		11	7
Restructuring charges, net of tax		7
Disposable glove facilities, Thailand
Restructuring Cost and Reserve [Line Items]
Deposit received on pending sale of assets				8
Net book value of disposable glove facility				3
S&IP | Disposable glove facilities, Thailand
Restructuring Cost and Reserve [Line Items]
Net gain on sale of disposable glove facility		$12

Supplemental_Balance_Sheet_Inf2

Supplemental Balance Sheet Information - Accounts Receivable (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$227.70	$234.90
Allowance for sales discounts and doubtful accounts	-1.2	-1
Accounts receivable, net	$226.50	$233.90

Supplemental_Balance_Sheet_Inf3

Supplemental Balance Sheet Information - Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Inventory, LIFO, Net [Abstract]
Raw materials	$51.30	$48.40
Work in process	54.9	47.7
Finished goods	157.6	157.8
Supplies and other	0	0
Inventory, gross	263.8	253.9
Excess of FIFO or weighted-average cost over LIFO cost	-20.9	-21.7
Inventories, net	242.9	232.2
Inventory, Non-LIFO, Net [Abstract]
Raw materials	0.7	1.3
Work in process	0.5	0.3
Finished goods	36.9	37.5
Supplies and other	12	11.8
Inventory, gross	50.1	50.9
Inventories, net	50.1	50.9
Inventory, Net [Abstract]
Raw materials	52	49.7
Work in process	55.4	48
Finished goods	194.5	195.3
Supplies and other	12	11.8
Inventory, gross	313.9	304.8
Excess of FIFO or weighted-average cost over LIFO cost	-20.9	-21.7
Inventories, net	$293	$283.10

Supplemental_Balance_Sheet_Inf4

Supplemental Balance Sheet Information - Property, Plant and Equipment (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$581.20		$568.70
Less accumulated depreciation	-299.4		-290.9
Total	281.8		277.8
Depreciation expense	10	9
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2.3		2.3
Buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	83.8		67.9
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	451.8		436.3
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$43.30		$62.20

Supplemental_Balance_Sheet_Inf5

Supplemental Balance Sheet Information - Schedule of Goodwill (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Goodwill [Roll Forward]
Balance at beginning of period	$1,426.10
Currency translation adjustment	-4
Balance at end of period	1,422.10
S&IP
Goodwill [Roll Forward]
Balance at beginning of period	744.5
Currency translation adjustment	-2.2
Balance at end of period	742.3
Medical Devices
Goodwill [Roll Forward]
Balance at beginning of period	681.6
Currency translation adjustment	-1.8
Balance at end of period	$679.80

Supplemental_Balance_Sheet_Inf6

Supplemental Balance Sheet Information - Intangible Assets with Indefinite Useful Lives (Details) (In-process research and development, USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
In-process research and development
Indefinite-lived Intangible Assets [Line Items]
Intangible assets with indefinite useful lives	$7	$7

Supplemental_Balance_Sheet_Inf7

Supplemental Balance Sheet Information - Schedule of Intangible Assets (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$324		$324
Accumulated Amortization	-228.9		-222.4
Net Carrying Amount	95.1		101.6
Amortization expense for intangible assets	6	8
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	126.6		126.6
Accumulated Amortization	-87.2		-86.1
Net Carrying Amount	39.4		40.5
Patents and acquired technologies
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	149.1		149.1
Accumulated Amortization	-103.8		-99.3
Net Carrying Amount	45.3		49.8
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	48.3		48.3
Accumulated Amortization	-37.9		-37
Net Carrying Amount	$10.40		$11.30

Supplemental_Balance_Sheet_Inf8

Supplemental Balance Sheet Information - Schedule of Estimated Amortization Expense (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2015	$18.90
2016	20.2
2017	14.9
2018	11.1
2019	6.9
Thereafter	23.1
Net Carrying Amount	$95.10	$101.60

Supplemental_Balance_Sheet_Inf9

Supplemental Balance Sheet Information - Schedule of Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued rebates	$68.30	$82.20
Accrued salaries and wages	27.4	46.4
Accrued taxes - income and other	23.8	23.4
Deposit received on pending sale of assets	0	7.8
Other	25.5	23.6
Total	$145	$183.40

Recovered_Sheet1

Supplemental Balance Sheet Information - Schedule of Other Long-Term Liabilities (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred income taxes	$27.80	$27.90
Taxes payable	1.6	1.6
Other	22.8	18.6
Total	$52.20	$48.10

LongTerm_Debt_Schedule_of_Debt

Long-Term Debt - Schedule of Debt (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Debt Instrument [Line Items]
Total long-term debt	$635.30	$636.20
Less debt payable within one year	3.9	3.9
Long-term portion	631.4	632.3
Secured debt | Term loan facility
Debt Instrument [Line Items]
Weighted-Average Interest Rate	4.00%
Total long-term debt	385.3	386.2
Unsecured debt | 6.25% Senior Notes
Debt Instrument [Line Items]
Weighted-Average Interest Rate	6.25%
Total long-term debt	$250	$250

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Details) (USD $)	3 Months Ended	1 Months Ended	0 Months Ended
	Mar. 31, 2015	6-May-15	Apr. 30, 2015
Secured debt | Term loan facility
Debt Instrument [Line Items]
Weighted-average interest rate	4.00%
6.25% Senior Notes | Unsecured debt
Debt Instrument [Line Items]
Weighted-average interest rate	6.25%
Credit Facility | Revolving credit facility
Debt Instrument [Line Items]
Unused capacity, commitment fee percentage	0.40%
Consolidated total leverage ratio	2.25
Credit Facility | Revolving credit facility | Leverage Ratio, Less than 2.25
Debt Instrument [Line Items]
Unused capacity, commitment fee percentage	0.25%
Credit Facility | Revolving credit facility | Base rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.75%
Credit Facility | Revolving credit facility | Base rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
Credit Facility | Revolving credit facility | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.75%
Credit Facility | Revolving credit facility | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2.50%
Credit Facility | Secured line of credit
Debt Instrument [Line Items]
Borrowing capacity	640,000,000
Credit Facility | Secured line of credit | Revolving credit facility
Debt Instrument [Line Items]
Borrowing capacity	250,000,000
Term of credit facility	5 years
Credit Facility | Secured line of credit | Letter of credit
Debt Instrument [Line Items]
Borrowing capacity	75,000,000
Credit Facility | Secured line of credit | Swingline sub-facility
Debt Instrument [Line Items]
Borrowing capacity	25,000,000
Credit Facility | Secured line of credit | Term loan facility
Debt Instrument [Line Items]
Borrowing capacity	390,000,000
Term of credit facility	7 years
Credit Facility | Secured debt | Revolving credit facility
Debt Instrument [Line Items]
Amount outstanding	0
Amount available for borrowing	247,000,000
Credit Facility | Secured debt | Letter of credit
Debt Instrument [Line Items]
Amount outstanding	3,000,000
Credit Facility | Scenario 1 | Revolving credit facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%
Credit Facility | Scenario 2 | Revolving credit facility | Base rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.25%
Term loan facility | Secured debt | Revolving credit facility
Debt Instrument [Line Items]
Quarterly amortization payments	0.25%
Effective interest rate	4.00%
Term loan facility | Scenario 1 | Secured debt | Revolving credit facility | Base rate
Debt Instrument [Line Items]
Interest rate floor	0.75%
Term loan facility | Scenario 1 | Secured debt | Revolving credit facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate	3.25%
Term loan facility | Scenario 2 | Secured debt | Revolving credit facility | U.S. federal funds effective rate
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
Term loan facility | Scenario 3 | Secured debt | Revolving credit facility | Base rate
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%
Term loan facility | Scenario 3 | Secured debt | Revolving credit facility | One month LIBOR Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Subsequent Event
Debt Instrument [Line Items]
Write-off of related debt issuance costs and original issue discount		1,000,000
Subsequent Event | Secured debt | Term loan facility
Debt Instrument [Line Items]
Principal repayments on senior secured term loan			$50,000,000

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Details) (Foreign exchange contracts, USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Undesignated hedging instruments
Derivative [Line Items]
Aggregate notional amount	$70
Cash flow hedges | Designated as Hedging Instrument
Derivative [Line Items]
Aggregate notional amount	39
Fair Value, Inputs, Level 2
Derivative [Line Items]
Derivative liabilities	$1	$1

Fair_Value_Information_Details

Fair Value Information (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Fair Value, Inputs, Level 1 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$166.20	$149
Fair Value, Inputs, Level 1 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	166.2	149
Fair Value, Inputs, Level 2 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	635.3	636.2
Fair Value, Inputs, Level 2 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	656.2	644
Foreign exchange contracts | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	$1	$1

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Equity [Abstract]
Unrealized translation	($6.80)	$2.60
Cash flow hedges	0.5	2.9
Other comprehensive income (loss), before tax	-6.3	5.5
Tax effect	-0.2	-0.5
Total Other Comprehensive (Loss) Income, Net of Tax	($6.50)	$5

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Option Activity (Details) (USD $)	3 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Mar. 31, 2015
Shares
Beginning of the period	611
Granted	336
Forfeitures	-21
End of the period	926
Weighted- Average Exercise Price
Beginning of the period	$34.94
Granted	$45.51
Forfeitures	$35.52
End of the period	$38.76
Weighted- Average Remaining Contractual Term	9 years 1 month 6 days
Aggregate Intrinsic Value	$9.70

StockBased_Compensation_Option

Stock-Based Compensation - Options Outstanding, By Exercise Price Range (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, in shares	926
Weighted- Average Remaining Contractual Term	9 years 1 month 6 days
$25 to $35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	25
Range of Exercise Prices, maximum	35
Options Outstanding, in shares	252
Weighted- Average Remaining Contractual Term	7 years 9 months 18 days
$35 to $45
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	35
Range of Exercise Prices, maximum	45
Options Outstanding, in shares	339
Weighted- Average Remaining Contractual Term	9 years 3 months 18 days
$45 plus
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	45
Options Outstanding, in shares	335
Weighted- Average Remaining Contractual Term	9 years 10 months 24 days

StockBased_Compensation_Restri

Stock-Based Compensation - Restricted Share Units Activity (Details) (Restricted Stock Units, USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Restricted Stock Units
Shares
Beginning of the period	375
Granted	103
Forfeitures	-8
End of the period	470
Vested at end of the period	27
Weighted- Average Fair Value
Beginning of the period	$37.88
Granted	$45.63
Forfeitures	$37.88
End of the period	$39.59
Vested at end of the period	$44.32

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$5
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	1
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	4
Kimberly-Clark Incentive Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$1

Earnings_Per_Share_EPS_Details

Earnings Per Share ("EPS") (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Net Income	$21.70	$41.40
Basic weighted average shares outstanding	46.5	46.5
Dilutive effect of stock options and restricted share unit awards	0.2	0
Diluted weighted average shares outstanding	46.7	46.5
Basic	$0.47	$0.89
Diluted	$0.46	$0.89

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Net Sales	$394.20	$410.70
Operating Profit	40.9	61.7
Other income, net	12	0.5
Interest income	0.1	1
Interest expense	-8.3	0
Income before Income Taxes	32.7	62.7
Spin-off
Segment Reporting Information [Line Items]
Restructuring charges	11	7
S&IP | Disposable glove facilities, Thailand
Segment Reporting Information [Line Items]
Net gain on sale of disposable glove facility	12
Operating segments | S&IP
Segment Reporting Information [Line Items]
Net Sales	254.8	275.5
Operating Profit	19.5	40.1
Operating segments | Medical Devices
Segment Reporting Information [Line Items]
Net Sales	122.3	129.6
Operating Profit	24.8	31.4
Corporate, non-segment
Segment Reporting Information [Line Items]
Net Sales	17.1	5.6
Operating Profit	($15.40)	($10.30)

Related_Party_Transactions_Det

Related Party Transactions (Details) (Kimberly Clark and Affiliates, Affiliated entity, USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Related Party Transaction [Line Items]
Allocated expenses	$25
Cost of products sold
Related Party Transaction [Line Items]
Allocated expenses	6
Selling and general expenses
Related Party Transaction [Line Items]
Allocated expenses	16
Research expenses
Related Party Transaction [Line Items]
Allocated expenses	$3